MX2023012779A - Regimenes de dosificacion de conjugados de peptido de inhibidores de topoisomerasa i. - Google Patents

Regimenes de dosificacion de conjugados de peptido de inhibidores de topoisomerasa i.

Info

Publication number
MX2023012779A
MX2023012779A MX2023012779A MX2023012779A MX2023012779A MX 2023012779 A MX2023012779 A MX 2023012779A MX 2023012779 A MX2023012779 A MX 2023012779A MX 2023012779 A MX2023012779 A MX 2023012779A MX 2023012779 A MX2023012779 A MX 2023012779A
Authority
MX
Mexico
Prior art keywords
topoisomerase
inhibitors
dosing regimens
peptide conjugates
peptide
Prior art date
Application number
MX2023012779A
Other languages
English (en)
Spanish (es)
Inventor
Vishwas Paralkar
Arthur P Decillis
Original Assignee
Cybrexa 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 2 Inc filed Critical Cybrexa 2 Inc
Publication of MX2023012779A publication Critical patent/MX2023012779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023012779A 2021-04-29 2022-04-28 Regimenes de dosificacion de conjugados de peptido de inhibidores de topoisomerasa i. MX2023012779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163181640P 2021-04-29 2021-04-29
PCT/US2022/071967 WO2022232808A1 (en) 2021-04-29 2022-04-28 Dosing regimens of peptide conjugates of topoisomerase i inhibitors

Publications (1)

Publication Number Publication Date
MX2023012779A true MX2023012779A (es) 2024-01-16

Family

ID=81749580

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012779A MX2023012779A (es) 2021-04-29 2022-04-28 Regimenes de dosificacion de conjugados de peptido de inhibidores de topoisomerasa i.

Country Status (12)

Country Link
US (1) US20240226308A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329817A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516825A (cg-RX-API-DMAC7.html)
KR (1) KR20240019097A (cg-RX-API-DMAC7.html)
CN (1) CN117897175A (cg-RX-API-DMAC7.html)
AU (1) AU2022267389A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218253A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003187A1 (cg-RX-API-DMAC7.html)
IL (1) IL308052A (cg-RX-API-DMAC7.html)
MX (1) MX2023012779A (cg-RX-API-DMAC7.html)
TW (1) TW202308696A (cg-RX-API-DMAC7.html)
WO (1) WO2022232808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
CA3032186C (en) 2010-07-13 2022-04-26 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20210106648A1 (en) * 2019-10-11 2021-04-15 TOBEBIO Novel Drug Laboratory Co., Ltd. Synergistic combination of chemotherapy and peptide for treating cancer

Also Published As

Publication number Publication date
KR20240019097A (ko) 2024-02-14
CA3218253A1 (en) 2022-11-03
IL308052A (en) 2023-12-01
AU2022267389A9 (en) 2023-11-16
AU2022267389A1 (en) 2023-11-09
CN117897175A (zh) 2024-04-16
EP4329817A1 (en) 2024-03-06
US20240226308A1 (en) 2024-07-11
WO2022232808A1 (en) 2022-11-03
JP2024516825A (ja) 2024-04-17
CL2023003187A1 (es) 2024-05-03
TW202308696A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
PH12022550039A1 (en) Peptide conjugates of cytotoxins as therapeutics
MY209340A (en) Egfr inhibitor for the treatment of cancer
GEP20267886B (en) Exatecan derivatives and antibody-drug conjugates thereof
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
CY1121265T1 (el) Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2024000230A (es) Inhibidores de cdk2.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
CL2023003187A1 (es) Regímenes de dosificación de conjugados peptídicos de inhibidores de la topoisomerasa i.
MX2024002391A (es) Inhibidores de indolina de kif18a.
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2023013715A (es) Regímenes de dosis de ecubectedina.
PH12022550037A1 (en) Peptide conjugates of microtubule-targeting agents as therapeutics
MX2024006684A (es) Inhibidores de hdac novedosos y uso terapéutico de estos.
CL2024001486A1 (es) Conjugados peptidicos de inhibidores peptidicos de tubulina como terapeuticos.
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
MX2022007916A (es) Conjugados que experimentan rearreglos intramoleculares.
DOP2025000274A (es) Inhibidores de egfr para el tratamiento de enfermedades